Seventh Statin Appoved: Kowa Will Take A Niche Strategy For Livalo
This article was originally published in PharmAsia News
Executive Summary
Kowa's decision to emphasize its newly approved statin Livalo'seffect in populations that are hard to treat with other statins is a wise strategy for a late entry to a class dominated by popular generics and well-established brands from marketing powerhouses like Pfizer and AstraZeneca
You may also be interested in...
Kowa Livalo Deal With Mitsubishi Tanabe Highlights Broader Expansion Plans
Mitsubishi Tanabe Pharma has agreed to market Nagoya-based drug maker Kowa's cholesterol drug Livalo (pitavastatin) through subsidiaries in Taiwan and Indonesia in a deal that shows how nimble a mid-sized Japanese firm is quickly expanding outside the home market as it gears up to enter the U.S., Canada and Europe
Kowa Livalo Deal With Mitsubishi Tanabe Highlights Broader Expansion Plans
Mitsubishi Tanabe Pharma has agreed to market Nagoya-based drug maker Kowa's cholesterol drug Livalo (pitavastatin) through subsidiaries in Taiwan and Indonesia in a deal that shows how nimble a mid-sized Japanese firm is quickly expanding outside the home market as it gears up to enter the U.S., Canada and Europe
Novartis To Seek Licensing Partner For Pitavastatin
The firm is terminating development of its lipid-lowering agent pitavastatin after disappointing Phase II trial results.